Warning Letter — Jabil Inc.
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to Jabil Inc. on August 27, 2026, following an agency evaluation.
This action affects Jabil Inc. and its associated pharmaceutical manufacturing operations, quality management systems, and regulatory compliance departments.
A Warning Letter from CDER typically indicates significant deviations from cGMP or other regulatory requirements. For a large-scale manufacturer, this may suggest systemic quality oversight issues that could impact production timelines, supply chain reliability, and the status of pending drug applications. The involvement of CDER implies the concerns are specific to drug product or component manufacturing rather than medical devices.
Quality teams should conduct a thorough audit of site-specific compliance at contract manufacturing locations and ensure all CDER-regulated processes align with current good manufacturing practice (cGMP) standards. Regulatory affairs should review any outstanding inspection observations that may have led to this escalated enforcement action.
FDA Warning Letter issued to: Jabil Inc.. 08/27/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jabil-inc-731037-08272026
Open in openFDA / FDA.gov